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Background   Bisphosphonates increase the callus size and 
strength in animal fracture studies. In a human non-randomized 
pilot study of high tibial osteotomies in knee osteoarthritis, using 
the hemicallotasis (HCO) technique, bisphosphonates shortened 
the healing time by 12 days. In the present randomized study, we 
wanted to determine whether a single infusion of zoledronic acid 
reduces the time to clinical osteotomy healing. Results from the 
same trial, showing improved pin fixation with zoledronate, have 
been published separately. 
Methods   46 consecutive patients (aged 35–65 years) were oper-
ated. At 4 weeks postoperatively, the patients were randomized to 
an intravenous infusion of either zoledronic acid or sodium chlo-
ride. Dual-energy X-ray absorptiometry (DEXA) was performed 
10 weeks postoperatively. Radiographs were taken at 10 weeks 
and every second week until there was radiographic and clinical 
healing. Healing was evaluated blind, with extraction of the exter-
nal fixator as the endpoint. At 1.5 years, an additional radiograph 
was taken and the hip-knee-ankle (HKA) angle measured to eval-
uate whether correction had been retained.
Results   All osteotomies healed with no difference in healing 
time between the groups (77 (SD 7) days). Bone mineral density 
and bone mineral content, as assessed with DEXA, were similar 
between the groups. Radiographically, both groups had retained 
the acquired correction at the 1.5-year follow-up.
Interpretation   In this randomized comparison, a single infu-
sion of zoledronic acid increased the pin fixation of the external 
frame but did not shorten the healing time. In both groups, the 
external fixator was extracted almost 2 weeks earlier than in pre-
vious studies. The early extraction did not cause a loss of correc-
tion in either group.
 
Pharmaceutical substances, both anabolic and anti-catabolic, 
have been used to modulate fracture healing (for a review, see 
Aspenberg 2005). Anabolic drugs such as parathyroid hor-
mone (PTH) or bone morphogenic protein (BMP) influence 
the osteoblasts, either unspecifically by increasing recruit-
ment and proliferation, or specifically by directing the pro-
genitor cells into the osteoblastic lineage (Schindeler et al. 
2008). Anti-catabolic drugs such as bisphosphonates reduce 
the osteoclastic activity, and have been shown to increase the 
strength of a healing fracture by retaining the new-formed 
callus (Amanat et al. 2007).
Both anabolic and anti-catabolic drugs can therefore affect 
fracture healing, but the efficiency and mode of action of 
these drugs appear to differ between open and closed fractures 
(Tägil et al. 2010). In open fractures and other fractures asso-
ciated with delayed union like distal tibial fractures, a specific 
anabolic drug such as a BMP sometimes appears to be neces-
sary (Little et al. 2005, Ristiniemi et al. 2007). In a fracture 
in a cell-rich, well-vascularized environment an anti-catabolic 
drug might be sufficient (Amanat et al. 2007). Several argu-
ments can be put forward for both the clinician and the patient 
to use an anti-catabolic drug instead of an anabolic one for 
these fractures. Apart from being considerably more expen-
sive, the existing anabolic drugs have to be delivered into the 
fracture gap directly (BMP) or injected daily during the heal-
ing time (PTH). 
In this study, we wanted to determine whether an anti-cata-
bolic drug would reduce the time to healing in a well-vascu-
larized fracture, using HCO in knee osteoarthritis as a rela-
tively standardized and relatively frequent human model of 
bone healing. In a non-randomized pilot study of 24 patients 
operated on by HCO, 12 patients were treated with one single 
infusion of zoledronic acid and 12 were not. In the treatment 
group, the frame was removed after 78 (SD 13) days as com-
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(Tägil et al. 2006). In a previous study from the same group 
studying the influence of smoking, the treatment time in exter-
nal fixator was 96 days in non-smoking patients (W-Dahl and 
Toksvig-Larsen 2004). 
In the present randomized study, the primary outcome was 
clinical fracture healing, evaluated blind, and we wanted to 
determine whether one single infusion of zoledronic acid 
could reduce the time to fracture healing. As secondary out-
come, we evaluated the pin fixation and found almost 100% 
improvement in pin fixation in the uncoated pin in diaphyseal 
bone (Harding et al. 2010). Furthermore, the bone mineral 
density and bone mineral content of the osteotomy gap were 
compared between groups to monitor the biological effect of 
the single dose. Drug safety was evaluated, as well as the sub-
jective outcome as measured with the knee-specific KOOS 
questionnaire. Finally, we examined whether the surgically 
achieved correction was maintained, using radiographic hip-
knee-ankle (HKA) angle measurement after 1.5 years.
Patients and methods
Between February 2006 and May 2007, 46 patients (36 men) 
with a mean age of 49 (37–63) years (Table 1) who were oper-
ated on for knee osteoarthritis by the hemicallotasis technique 
(HCO) were included in the study (Figure 1). 41 patients had 
medial compartment osteoarthritis and 5 patients had lat-
eral compartment osteoarthritis. Inclusion criteria were age 
between 35 and 65 years and osteoarthritis or deformity of 
the knee requiring surgery. Exclusion criteria were kidney, 
liver, or odontological disorders; rheumatoid arthritis; or 
bisphosphonate treatment two years or less before surgery. 
Preoperatively, the patients were given written and oral infor-
mation and informed consent was obtained. The study was 
performed in compliance with the Helsinki Declaration and 
was approved by both the local ethics committee of Lund Uni-
versity (2006-03-02; registration number 554/2005) and the 
Swedish Medical Product Agency, and was registered in the 
EUDRACT database. It was externally monitored by a hos-
pital-based but independent organization (RSKC, Lund Uni-
versity Hospital). All patients who met the inclusion criteria 
were prescribed daily oral calcium and vitamin D3 the first 
6 weeks postoperatively, to avoid hypocalcemia if given the 
active drug. 
Surgery and randomization 
The HCO was performed as an outpatient procedure using the 
Orthofix T-garche external fixator (Magyar et al. 1998) (Figure 
2). 4 conical stainless steel pins were inserted: 2 hydroxyapa-
tite- (HA-) coated pins (Orthofix, Bussolengo, Italy) in the 
metaphyseal bone and 2 uncoated pins (Orthofix) in the diaph-
yseal bone. The patients were allowed free mobilization and 
full weight bearing after the operation. The distraction started 
7–10 days postoperatively. The patient made the correction by 
adjusting a distractor placed at the external fixator, one quarter 
of a turn 4 times per day, with the first turn in the morning and 
the last turn in the afternoon. Correction was measured by the 
hip-knee-ankle (HKA) angle of the knee during the corrective 
phase until the desired correction was achieved—4° valgus for 
the varus knee and 0–2° varus for the valgus knee—and the 
instrument was locked. The HKA angle was measured radio-
graphically on an anteroposterior view of the lower limb (hip, 
knee, and ankle) with the patient standing and weight bearing. 
By drawing a line from the center of the femoral head to the 
midpoint of the spine of the tibial eminence and another line 
from this midpoint to the center of the talus surface of the 
Table 1. Patient characteristics
  Zoledronate   Control
  group group
  (n = 25)  (n = 21)
Men/women    19/6    17/4
Mean age in years (SD)    48 (7)    50 (5)
Mean pre-HKA in degrees (SD)  173 (6)  173 (5)
Mean BMI (SD)    28 (3)    26 (3)
Smoker      4      7
Unsmoked tobacco user      4      6
HKA: hip-knee-ankle angle (< 180° = varus). 
Figure 1. A CONSORT flow diagram depicting patient recruitment, ran-
domization, patient flow, and follow-up in the study.
Assessed for eligibility
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– Not meeting the inclusion
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– Refused to participate 
   (n=13)
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Lost to follow-up HKA (n=0)
Discontinued HKA (n=0)
Lost to follow-up DEXA (n=1)
– Failed to appear (n=1)
Discontinued intervention
DEXA (n=0)
Allocated to intervention
zoledronate 4 mg (n=25)
Received allocated 
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Did not receive intervention
(n=0)
Lost to follow-up HKA (n=2)
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Lost to follow-up DEXA (n=1)
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(n=0)
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ankle joint, the mechanical axis of the limb could be calcu-
lated (Siu et al. 1991). The medial angle between the lines is 
the HKA angle (varus < 180°). The accuracy and reproduc-
ibility of measurement of the HKA angle has been shown to 
be within 2° (Odenbring et al. 1993).
4 weeks postoperatively, randomization was performed 
by one of the authors (AWD) using closed envelopes. The 
patient received an infusion of either zoledronic acid (4 mg 
intravenously) (Zometa; Novartis Pharma GmbH, Basel, 
Switzerland) or sodium chloride (9 mg/mL) prepared by the 
unblinded nurse. The infusion of zoledronic acid was prepared 
by diluting 4 mg zoledronic acid in 100 mL sodium chloride (9 
mg/mL) and the zoledronic acid or saline solution was given 
as a 15-min intravenous infusion. The patients were blinded 
regarding the type of infusion. If a patient reported signs of 
hypocalcemia at the follow up, serum calcium was measured. 
Outcome: Time to healing
At 8 weeks postoperatively, radiographs of the lower leg were 
obtained without weight bearing, and at 10 weeks the first 
evaluation of healing, blinded, on radiographs and ultrasound 
was done. The ultrasonic examination shows unmineralized 
callus formation in the distracted area earlier than conventional 
radiographs. When the callus was judged to be sufficient by 
radiographic examination (consolidation of about two-thirds 
of the osteotomy gap) and ultrasonic examination, the patient 
did a weight-bearing test, i.e. walking without the fixator but 
the pins still in situ for 2–48 hours. If the patient reported 
symptoms of incomplete healing, mainly pain by loading, the 
fixator was re-applied for 2 additional weeks (Table 2). The 
patient was checked radiographically every second week, and 
by ultrasound examination—until healing of the bone, again 
under blinding, was satisfactory (Magyar et al. 1998). 
KOOS (clinical outcome)
The form for the patient-relevant outcome measure (KOOS) 
(Roos et al. 1998a, b) was filled in preoperatively, and at 8 and 
10 weeks and every second week postoperatively, until extrac-
tion of the external fixation. It was also filled in at the 20-week 
and 1.5-year follow-up. 
Evaluation of densitometry
Dual-energy X-ray absorptiometry (DEXA) of the operated 
lower leg and bilateral proximal femur was performed at 10 
weeks postoperatively. The fixator was removed but the pins 
were still in place. The DEXA scans were centered anteropos-
teriorly over the osteotomy and 2–3 scans were performed to 
avoid over-projection of the fibula. Only 1 of the scans was 
used for evaluation. The region of interest (ROI) was centered 
over the osteotomy, including the edges. When the osteotomy 
gap was almost consolidated at the DEXA images, the borders 
of the osteotomy were measured on the corresponding radio-
graph and transferred to the DEXA image. The bone mineral 
density (BMD) and the bone mineral content (BMC) were 
measured. The total T-score of the proximal femur was used 
to determine whether the patients had osteoporosis (< –2.5 
SD), osteopenia (–1 to –2.5 SD), or normal bone. All scans 
were performed using GE Lunar Prodigy 16196 (Lunar BMP 
Products, Madison, WI).
Evaluation of the retention of surgically achieved cor-
rection
Radiographs were taken at mean 20 (SD 2) months after 
surgery, with measurement of the HKA angle to determine 
whether the correction was retained. All radiographs were 
analyzed and measured by one radiologist (MG). The value 
of the HKA angle was compared to an estimated angle of the 
Figure 2. Hemicallotasis osteotomy using the Orthofix 
T-garche as external fixator. A. Successive lengthening 
takes place. The HKA angle is slowly normalized and the 
frame is locked at the desired angle. The frame is kept until 
bone healing. B. When sufficient callus appears to be pres-
ent by ultrasound and radiography, the frame is removed 
temporarily. The patient is allowed to bear weight before the 
final decision to remove the frame. This decision is made 
blind regarding the pharmacological treatment. C. Radio-
graph showing a healed osteotomy at 1.5 years.   A
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correction, i.e. 4° valgus for the varus knee and 0–2° varus for 
the valgus knee. This was used as a measurement of the reten-
tion of correction. 
Safety
All drug-related side effects and adverse events were regis-
tered prospectively during the study. Complications such as 
delayed healing (by definition, > 16 weeks in external fixation 
(W-Dahl and Toksvig-Larsen 2004)), non-union, septic arthri-
tis, deep venous thrombosis, loss of correction, etc. (includ-
ing replacement of pins and difficulties in correction) were 
recorded.
Statistics
A power analysis was performed based on the data from the 
pilot study. 25 samples would be needed in each group to 
achieve a power of 95% at p = 0.05 in a two-sided test, with an 
estimated mean difference of healing time of 20 days between 
the bisphosphonate group and the control group. All data were 
expressed as mean, and standard deviation of the mean or 95% 
confidence interval (CI). Student’s t test was used to test the 
differences between the groups, with p < 0.05 being consid-
ered statistically significant in a 2-sided test. Statistical analy-
sis was carried out using SPSS software version 16.0.
Results
Surgery
All osteotomies healed, and the time in external fixation was 
the same in both groups: 77 (95% CI: 75–80) days in the zole-
dronic-treated group and 77 (CI: 74–81) days in the control 
group. The mean difference was 0.2 (CI: –4.4 to 4.8) days. 17 
of 25 patients in the zoledronic group and 18 of 21 patients in 
the control group had healed after 10 weeks in external fixa-
tion (Table 2). No patients had signs of hypocalcemia.
KOOS
The KOOS score improved over time. The major improve-
ments in pain, symptoms, ADL, and QOL were already 
achieved during treatment in the external fixator, whereas for 
sports and recreation the improvements could be measured 
first after the external fixator had been removed. There were 
only small differences between the groups, none of them-
which were statistically significant. 
DEXA
2 of the patients were lost to follow–up by DEXA (n = 44). 
None of the remaining patients had osteoporosis. 3 patients 
in the zoledronic-treated group and 6 in the control group had 
osteopenia. BMD of the healing tissue in the osteotomy gap 
was 1.14 (SD 0.27) g/cm² in the zoledronic treated group, as 
compared to 1.01 (SD 0.18) g/cm² in the control group (p = 
0.1). BMC of the osteotomy gap was 6.2 (SD 2.3) g in the 
zoledronic treated and 5.2 (SD 2.3) g in the control group 
(p = 0.2).
HKA
2 patients were lost to follow-up at 1.5 years after surgery (n 
= 44). No difference were seen in the change of HKA angle 
between the groups. In both groups, the changes were less 
than the measurement error of 2 degrees: the mean change 
was 0.3 (SD 3.3) degrees in the zoledronic-treated group as 
compared to –1.0 (SD 3.3) degrees in the control group (p = 
0.2). When the patients with lateral knee osteoarthritis were 
excluded, the mean difference was 0.5 (SD 3.4) degrees in 
the zoledronic-treated group and –1.1 (SD 3.6) degrees in the 
control group (p = 0.2).
Safety
No difference was found between the 2 groups regarding com-
plications. One deep vein thrombosis was observed in the con-
trol group. 13 of 25 patients reported muscle pain and influ-
enza-like symptoms in the zoledronic group as compared to 2 
of 21 in the placebo group (RR = 5, CI: 1.3–20; p = 0.004). 
One serious adverse event was registered in the zoledronic 
group, in the form of chest pain due to pneumonia.
Discussion
In a non-randomized pilot study of 24 patients, operated on 
using the HCO technique, 12 patients were treated with a 
single infusion of zoledronic acid and 12 were not (Tägil et 
al. 2006). In that study, the external fixator was removed after 
mean 78 (SD 13) days in the treated group as compared to 91 
(SD 13) days in the untreated group (p = 0.02). In the pres-
ent randomized study, the mean healing time was 77 days in 
both groups, i.e. shorter than in the pilot study but also shorter 
than in a previous study, in which the mean healing time was 
96 days (W-Dahl and Toksvig-Larsen 2004). The follow-up 
and the methods used to evaluate healing were the same as 
in the previous studies from our group (W-Dahl and Toksvig-
Larsen 2004, 2008), and in all of them there was blinding as 
to treatment. A true shortening of the treatment time therefore 
occurred in this study, but this was unrelated to administration 
of the drug. A fear that extraction of the external fixator too 
Table 2. Number of patients who were healed 
at each evaluation time point
Week Zoledronate  Control  Total
  group group 
  (n = 25)  (n = 21)  (n = 46)
10   17  18  35
12   24  20  44
14   24  21  45
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early would cause a loss of the surgically achieved HKA cor-
rection could not be verified at the late radiographic control. 
No loss of correction was found in either group 1.5 years after 
surgery, and the values measured were within the measure-
ment error. 
With the time from surgery to extraction shortened in both 
groups, it appears that the experimental protocol was inappro-
priate for finding differences. The first evaluation of healing 
was done after 10 weeks, i.e. a time point close to the short-
ened clinical healing time in both groups. Also, the DEXA 
scans were performed at 10 weeks after surgery and at this 
time point many of the osteotomies in both groups were 
healed. Perhaps an earlier time point for evaluation of the 
effect of the drug should have been used, but the time from 
administration of the drug to extraction would then have been 
less than 6 weeks, which at the time of design of the study was 
considered the minimum time for the drug to have an effect. 
The choice of time point for administration of the drug was 
based on animal experiments (Amanat et al. 2007). Bisphos-
phonates bind to bone mineral and if given at the time of on-
going fracture healing, a larger proportion binds to the frac-
ture site than if given earlier, for example at the time of the 
osteotomy. In animals, delayed administration of the bisphos-
phonate has been shown to have a superior effect compared 
both to saline and compared to zoledronic acid administered 
immediately at the time of the fracture (Amanat et al. 2007). 
A second reason for administration of the bisphosphonate at 
4 weeks was to avoid disturbing the initial bone formation, 
which has been feared both in in-vitro studies (Im et al. 2004) 
and, perhaps more importantly, in in-vivo studies (Jakobsen 
et al. 2007). 
2 other randomized studies have evaluated a drug regarding 
time to healing for a fracture in well-vascularized metaphy-
seal bone. PTH given as a daily injection was shown to reduce 
the time to healing in distal radial fractures by 1.7 weeks in a 
low-dose group (20 μg) but not in a high-dose group (Aspen-
berg et al. 2010). In a similar study comparing simvastatin 
and saline, also in distal radial fractures, no difference was 
found between the active compound and the control (Patil et 
al. 2009). Although both of these studies were in closed frac-
tures, in contrast to ours, which was made in surgically opened 
fractures; we believe that the studies are comparable. In our 
study, the osteotomy was performed in well-vascularized 
metaphyseal bone where the access to circulation and cells is 
high. It resembles a closed-fracture animal model and there is 
no need to bolster the anabolic part of the fracture healing, as 
in an open fracture with compromised bone formation. 
Based on the experience from animal experiments (Amanat 
et al. 2007, Harding et al. 2008), we used a potent bisphos-
phonate, zoledronic acid, which was administered as a single 
infusion 4 weeks after surgery. The dose was 4 mg, which 
was the dose used in treatment of malignancies at the time of 
design of the study, whereas the dose in osteoporosis today is 
5 mg. Zoledronate was not approved for osteoporosis at the 
time this trial started. No difference was found in BMD or 
BMC between the groups, which may indicate that a single 
dose, although efficient in animals, might be insufficient in 
humans. Perhaps a higher dose would have shortened the heal-
ing time, but the risk of side effects and unwanted effects such 
as local toxic effects to the osteoblasts would be higher. It is 
possible that continuous administration of a weekly oral dose 
of a bisphosphonate might have been more effective, but it is 
also possible that there is simply no or a very limited effect 
of the drug in this model. Given the reputation of the drug, 
which is feared to be a negative modulator in fracture healing, 
it should be emphasized that no negative effects of the drug 
regarding bone healing were found.
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